Overview
- The FDA’s Pharmacy Compounding Advisory Committee will review seven peptides for possible compounding on July 23–24, with its recommendation nonbinding and followed by agency rulemaking and public comment.
- Agency scientists have already advised against loosening restrictions because most of the seven peptides lack robust human trials, clear dosing guidelines, and data on long‑term risks.
- Telehealth firms, compounding pharmacies, and vendors have been preparing supply chains and clinical protocols and some clinics are already prescribing these peptides as demand grows.
- A broad online gray market sells research‑grade peptides labeled 'not for human use,' creating risks of contamination, wrong doses, and unsafe products if use expands.
- The debate builds on a 2023 policy that moved 19 peptides into a category that bars compounding, so any panel approval would not immediately legalize widespread dispensing and would reshape a market driven by social media and commercial pressure.